{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T14:52:18Z","timestamp":1718290338267},"reference-count":34,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The antibacterial effects (ABE) of tomopenem (formerly RO4908463\/CS-023) against seven\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            strains (methicillin-resistant\n            <jats:italic>S. aureus<\/jats:italic>\n            [MRSA] strain tomopenem MICs, 0.5 to 16 mg\/liter; methicillin-sensitive\n            <jats:italic>S. aureus<\/jats:italic>\n            [MSSA] strain tomopenem MIC, 0.06 mg\/liter) were studied in an in vitro pharmacokinetic model. Initially, two human doses were simulated, 750 mg every 8 hours (8hly) and 1,500 mg 8hly intravenously, using\n            <jats:italic>S. aureus<\/jats:italic>\n            at a standard inoculum of 10\n            <jats:sup>6<\/jats:sup>\n            CFU\/ml. There was a rapid clearance of bacteria from the model by 12 h after drug exposure with most strains. Clearance was not related to the tomopenem MIC. The ABE of these two tomopenem dose regimens were also tested at a high inoculum, 10\n            <jats:sup>8<\/jats:sup>\n            CFU\/ml; in all simulations, there was a &gt;4-log drop in viable count at 24 h. Strains were not cleared from the model at 10\n            <jats:sup>8<\/jats:sup>\n            CFU\/ml, in contrast to what was seen for the standard inoculum. When the ABE of tomopenem at 750 mg 8hly was compared to those of vancomycin, tomopenem was seen to have a superior effect, as measured by the area under the bacterial kill curve at 24 h (AUBKC\n            <jats:sub>24<\/jats:sub>\n            ) and 48 h (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). Dose ranging studies were performed to provide time-above-MIC (T&gt;MIC) drug exposures of 0 to 100% (8 to 10 doses per strain) with five MRSA\/MSSA strains. The T&gt;MIC for a 24-h bacteriostatic effect was 8% \u00b1 5% (range, 1.3% to 15.4%); the T&gt;MIC for a 4-log drop in viable count was 32% \u00b1 18% (range, 12.8% to 36.2%). The T&gt;MIC for a 90% maximum response using AUBKC\n            <jats:sub>24<\/jats:sub>\n            as ABE was 24.9% \u00b1 15.7%. Inoculum had little impact on T&gt;MIC exposures for ABE. There was emergence of resistance to tomopenem in the dose ranging studies, with increased growth of subpopulations on plates containing tomopenem at 2\u00d7 and 4\u00d7 the MIC compared to what was seen for preexposure population analysis at T&gt;MICs of &lt;20%. The pharmacodynamics of tomopenem against\n            <jats:italic>S. aureus<\/jats:italic>\n            is similar to those of other members of the carbapenem class, with the exception that MRSA is included. These data indicate that tomopenem will have clinically useful activity against MRSA at T&gt;MICs achievable in humans.\n          <\/jats:p>","DOI":"10.1128\/aac.01153-07","type":"journal-article","created":{"date-parts":[[2008,1,29]],"date-time":"2008-01-29T01:46:57Z","timestamp":1201571217000},"page":"1401-1406","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463\/CS-023, in an In Vitro Pharmacokinetic Model of\n            <i>Staphylococcus aureus<\/i>\n            Infection"],"prefix":"10.1128","volume":"52","author":[{"given":"Alasdair P.","family":"MacGowan","sequence":"first","affiliation":[{"name":"Bristol Centre for Antimicrobial Research &amp; Evaluation, Department of Medical Microbiology, Southmead Hospital, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen E.","family":"Bowker","sequence":"additional","affiliation":[{"name":"Bristol Centre for Antimicrobial Research &amp; Evaluation, Department of Medical Microbiology, Southmead Hospital, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R.","family":"Noel","sequence":"additional","affiliation":[{"name":"Bristol Centre for Antimicrobial Research &amp; Evaluation, Department of Medical Microbiology, Southmead Hospital, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"10","year":"2003","unstructured":"Andes, D. R., S. Kiem, and W. A. Craig. 2003. In vivo pharmacodynamic activity of a new carbapenem, doripenem, against multiple bacteria in a murine thigh infection model, A-308, p. 10. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1376-1383.2006"},{"key":"e_1_3_2_4_2","first-page":"199","year":"2006","unstructured":"Andes, D. R., and W. A. Craig. 2006. In vivo pharmacodynamic activity of a new carbapenem, PZ601, against multiple bacteria in murine thigh and lung infection models. F1-232, p. 199. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, San Francisco, CA.","journal-title":"Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother."},{"key":"e_1_3_2_5_2","first-page":"35","year":"1999","unstructured":"Andrews, J. 1999. Microbiological assays, p. 35-45. In D. S. Reeves, R. Wise, J. M. Andrews, and L. O. White (ed.), Clinical antimicrobial assays. Oxford University Press, Oxford, United Kingdom.","journal-title":"Clinical antimicrobial assays."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/jac\/38.6.1055","volume":"38","year":"1996","unstructured":"Bowker, K. E., H. A. Holt, D. S. Reeves, and A. P. MacGowan. 1996. Bactericidal activity, post antibiotic effect and modified effective regrowth time of meropenem at high concentrations. J. Antimicrob. Chemother.38:1055-1060.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.4.461"},{"key":"e_1_3_2_8_2","first-page":"5","volume":"46","year":"2001","unstructured":"British Society for Antimicrobial Chemotherapy, Working Party. 2001. Antimicrobial susceptibility testing. J. Antimicrob. Chemother.46(Suppl. S1):5-16.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_9_2","unstructured":"P-16663. Abstr. 17th Eur. Congr. Clin. Microbiol. Infect. Dis.\/25th Int. Congr. Chemother. 2007"},{"key":"e_1_3_2_10_2","unstructured":"CLSI document M100-S16. 2005"},{"key":"e_1_3_2_11_2","first-page":"1","year":"2002","unstructured":"Craig, W. A. 2002. Pharmacodynamics of antimicrobials: general concepts and applications, p. 1-22. In C. H. Nightingale, T. Murakawa, and P. G. Ambrose (ed.). Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker Inc., Basel, Switzerland.","journal-title":"Antimicrobial pharmacodynamics in theory and clinical practice."},{"key":"e_1_3_2_12_2","first-page":"119","volume":"23","year":"1989","unstructured":"Della Bruna, C., D. Jabes, R. Rossi, G. Younes, and P. Castellani. 1989. FCE 22101 and FCE 22891: in vitro antibacterial activity at concentrations simulating human plasma levels following intravenous, intramuscular and oral administration. J. Antimicrob. Chemother.23(Suppl. C):119-128.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/jac\/dkl355","volume":"58","year":"2006","unstructured":"Fernandes Guerrero, M. L., and M. de Gorgolas. 2006. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis. J. Antimicrob. Chemother.58:1066-1069.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/jac\/24.suppl_A.239","volume":"24","year":"1989","unstructured":"Ferrari, A., G. Grassi, F. A. Grassi, P. D. Piccioni, and G. Gialdroni Grassi. 1989. Bactericidal activity of meropenem and interactions with other antibiotics. J. Antimicrob. Chemother.24(Suppl. A):239-250.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.352"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.9.1905"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3109\/00365549509047048","volume":"27","year":"1995","unstructured":"Fuentes, F., M. M. Martin, J. Izquierdo, M. L. Gomez-Lius, and J. Prieto. 1995. In vivo and in vitro study of several pharmacodynamic effects of meropenem. Scand. J. Infect. Dis.27:469-474.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_18_2","first-page":"65","year":"2006","unstructured":"Jones, M. E., M. A. Cohen, N. P. Brown, B. Dannemann, and D. F. Sahm. 2006. RO4908463 demonstrates a low potential for in vitro selection of resistance in S. aureus, E. coli, and P. aeruginosa, abstr. C1-35, p. 65. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, San Francisco, CA.","journal-title":"Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.7164\/antibiotics.56.565","volume":"56","year":"2003","unstructured":"Kawamoto, I., Y. Skinoji, O. Kanno, K. Kojima, K. Ishikawa, E. Matsuyama, Y. Ashida, T. Shibayama, T. Fukuoka, and S. Ohya. 2003. Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. J. Antibiot. (Tokyo)56:565-579.","journal-title":"J. Antibiot. (Tokyo)"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3239-3250.2005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.2.281"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-9-674"},{"key":"e_1_3_2_23_2","unstructured":"Clinical antibiotic assays. 1999"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1088-1095.2003"},{"key":"e_1_3_2_25_2","first-page":"295","volume":"27","year":"1993","unstructured":"Maggiolo, F., A. Tarus, S. Frontespezi, F. Bottari, M. C. Legnani, and F. Suter. 1993. Bactericidal activity of two different dosage regimens of imipenem in an in vitro dynamic model. J. Antimicrob. Chemother.27:295-300.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2083"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.8.1723"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.8.1735"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1179\/joc.1999.11.5.323","volume":"11","year":"1999","unstructured":"Periti, P., and P. Nicoletti. 1999. Classification of betalactam antibiotics according to their pharmacodynamics. J. Chemother.11:323-330.","journal-title":"J. Chemother."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00494-06"},{"key":"e_1_3_2_31_2","first-page":"257","volume":"50","year":"2007","unstructured":"Shibayama, T., Y. Matsushita, K. Kawal, T. Hirota, T. Ikeda, and S. Kuwahara. 2007. Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals. Antimicrob. Agents Chemother.50:257-263.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.6.1227"},{"key":"e_1_3_2_33_2","first-page":"140","volume":"5","year":"1998","unstructured":"Svensson, E., H. Hanberger, M. Nilsson, and L. E. Nilsson. 1998. Pharmacodynamic effects of amikacin, ciprofloxacin and imipenem on growing and non-growing Escherichia coli and Pseudomonas aeruginosa. Clin. Microbiol. Infect.5:140-148.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh328"},{"key":"e_1_3_2_35_2","first-page":"147","year":"1994","unstructured":"Walker, R., D. Andes, R. Comlin, S. Ebert, and W. Craig. 1994. Pharmacodynamic activities of meropenem in an animal model, abstr. A91, p. 147. Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Orlando, FL.","journal-title":"Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01153-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01153-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:35:14Z","timestamp":1645472114000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01153-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1128\/AAC.01153-07"],"URL":"https:\/\/doi.org\/10.1128\/aac.01153-07","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"2007-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-01-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}